ClinicalTrials.gg
Active, not recruitingNCT05766501Updated Dec 17, 2025

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

A Phase 3 interventional study of DOR/ISL in HIV Infection, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 95 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
641
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in HIV Infections by Merck & Co., Inc — 1 open to participants now, 2 under way, 1 of them phase 3. HIV Infections · Merck & Co., Inc.

Enrollment
7th of 66
641 · median 163
Started
2023
the only one that year
Phase 3
21 of 75
none open now
Registered
73rd of 75
by date

Among the 75 studies in HIV Infections by Merck & Co., Inc, this one is the 7th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2023, is one of 21 in phase 3, and was the 73rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 75 studies in HIV Infections by Merck & Co., Inc is open now. Recruiting first, the newest first:

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in HIV Infections by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies. There are no formal hypotheses to be tested in this study.

03

Conditions studied

  • HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is currently receiving doravirine/islatravir (DOR/ISL) adult fixed dose combination (FDC) tablet in Merck Sharp \& Dohme (MSD)-sponsored clinical studies (MK-8591A-018, -020, and -033 [except for heavily treatment-experienced (HTE) participants]).

Exclusion criteria

Exclusion Criteria:

  • Has confirmed -1 RNA ≥200 copies/mL in MSD DOR/ISL (100 mg/0.75 mg) MK-8591A-018 /-020, or at screening for participants entering from DOR/ISL (100 mg/0.75 mg) MK-8591A-033.
  • Has confirmatory laboratory findings for cluster of differentiation 4+ (CD4+) T-cell counts or lymphocyte counts in the prior DOR/ISL study that meet criteria for discontinuation of DOR/ISL.
  • Is a HTE participant receiving treatment in MK-8591A-019 or -033.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
641 participants (actual)

Study arms

  • Experimental
    DOR/ISL

    Participants will receive fixed dose combination (FDC) tablet of DOR/ISL (100 mg/0.25 mg) taken once daily (QD) orally from Day 1 to Week 96. After Week 96, eligible participants may continue on DOR/ISL until week 240 or until DOR/ISL becomes commercially accessible, whichever comes first.

    Drug: DOR/ISL

Interventions

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily

    Also known as: MK-8591A, Doravirine/islatravir

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with One or More Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experience an AE through Week 96 will be presented.

    Time frame: Up to 96 Weeks

  2. Percentage of participants who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study intervention due to an AE through Week 96 will be presented.

    Time frame: Up to 96 Weeks

Secondary outcomes

  1. Percentage of Participants with HIV-1 Ribonucleic Acid (RNA) ≥50 copies/mL at Week 96

    The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 will be reported.

    Time frame: Week 96

  2. Percentage of Participants with HIV-1 RNA <50 copies/mL at Week 96

    The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 will be reported.

    Time frame: Week 96

  3. Percentage of Participants with HIV-1 RNA <200 copies/mL at Week 96

    The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 will be reported

    Time frame: Week 96

  4. Percentage of Participants with Evidence of Viral Drug Resistance-Associated Substitutions

    Viral drug resistance is defined as participants with HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic data showing evidence of resistance to the study intervention. The percentage of participants who demonstrate drug resistance through Week 96 will be presented.

    Time frame: Up to Week 96

07

Study locations

95 sites
  • University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 3104)
    Birmingham, Alabama 35222, United States
  • Pueblo Family Physicians ( Site 3102)
    Phoenix, Arizona 85015, United States
  • Pacific Oaks Medical Group ( Site 3123)
    Beverly Hills, California 90211, United States
  • Kaiser Permanente ( Site 3124)
    Los Angeles, California 90027, United States
  • Ruane Clinical Research Group, Inc ( Site 3126)
    Los Angeles, California 90036, United States
  • Mills Clinical Research ( Site 3114)
    Los Angeles, California 90069, United States
  • University of California Davis Health-Internal Medicine: Infectious Diseases ( Site 3137)
    Sacramento, California 95817, United States
  • Georgetown University Medical Center ( Site 3130)
    Washington D.C., District of Columbia 20007, United States
  • Therafirst Medical Center ( Site 3110)
    Fort Lauderdale, Florida 33308, United States
  • Midway Immunology and Research Center ( Site 3117)
    Ft. Pierce, Florida 34982, United States
  • AHF The Kinder Medical Group ( Site 3108)
    Miami, Florida 33133, United States
  • Floridian Clinical Research, LLC ( Site 3133)
    Miami Lakes, Florida 33016, United States
  • Orlando Immunology Center ( Site 3106)
    Orlando, Florida 32803, United States
  • Bliss Healthcare Services ( Site 3115)
    Orlando, Florida 32806, United States
  • CAN Community Health - Sarasota ( Site 3118)
    Sarasota, Florida 34237, United States
  • Triple O Research Institute, P.A ( Site 3116)
    West Palm Beach, Florida 33407, United States
  • Augusta University-Infectious Diseases ( Site 3135)
    Augusta, Georgia 30912, United States
  • Infectious Disease Specialists of Atlanta ( Site 3128)
    Decatur, Georgia 30033, United States
  • Mercer university, Department of internal medicine-Clinical Research ( Site 3129)
    Macon, Georgia 31201, United States
  • Chatham County Health Department - Chatham CARE Center-Infectious Disease ( Site 3105)
    Savannah, Georgia 31401, United States
  • KC CARE Health Center ( Site 3103)
    Kansas City, Missouri 64111, United States
  • ID Care ( Site 3131)
    Hillsborough, New Jersey 08844, United States
  • Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center ( Site 3134)
    New York, New York 10029, United States
  • Penn Medicine: University of Pennsylvania Health System-Perelman Center for Advanced Medicine ( Site
    Philadelphia, Pennsylvania 19104, United States
  • St Hope Foundation ( Site 3121)
    Bellaire, Texas 77401, United States
  • North Texas Infectious Diseases Consultants, P.A ( Site 3100)
    Dallas, Texas 75246, United States
  • Texas Centers for Infectious Disease Associates ( Site 3111)
    Fort Worth, Texas 76104, United States
  • The Crofoot Research Center ( Site 3101)
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research ( Site 3119)
    Longview, Texas 75605, United States
  • Private Practice - Dr. Peter Shalit ( Site 3120)
    Seattle, Washington 98104, United States
  • Multicare Institute for Research and Innovation ( Site 3127)
    Spokane, Washington 99202, United States
  • Instituto Oulton ( Site 1004)
    Córdoba, Córdoba Province X5000JJS, Argentina
  • Instituto CAICI SRL ( Site 1003)
    Rosario, Santa Fe Province S2000PBJ, Argentina
  • Helios Salud ( Site 1002)
    Buenos Aires, C1141ACG, Argentina
  • Fundación Huésped ( Site 1001)
    Buenos Aires, C1202ABB, Argentina
  • Fundación IDEAA ( Site 1005)
    Buenos Aires, C1405CKC, Argentina
  • Holdsworth House Medical Practice ( Site 1100)
    Darlinghurst, New South Wales 2010, Australia
  • St Vincent's Hospital-IBAC ( Site 1103)
    Sydney, New South Wales 2010, Australia
  • Holdsworth House Medical Practice - Brisbane ( Site 1101)
    Brisbane, Queensland 4006, Australia
  • Prahran Market Clinic ( Site 1102)
    Melbourne, Victoria 3181, Australia
  • Hamilton Health Sciences- Urgent Care Centre ( Site 1304)
    Hamilton, Ontario L8S 1A4, Canada
  • Maple Leaf Research ( Site 1301)
    Toronto, Ontario M5G 1K2, Canada
  • Toronto General Hospital ( Site 1300)
    Toronto, Ontario M5G 2C4, Canada
  • Clinique de médecine Urbaine du Quartier Latin ( Site 1305)
    Montreal, Quebec H2L 4E9, Canada
  • Clinique Medicale lActuel ( Site 1303)
    Montreal, Quebec H2L 4P9, Canada
  • McGill University Health Centre ( Site 1306)
    Montreal, Quebec H4A 3J1, Canada
  • Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 1403)
    Temuco, Araucania 4781151, Chile
  • Clinica Universidad Catolica del Maule ( Site 1405)
    Talca, Maule Region 3460000, Chile
  • Biomedica Research Group-Infectology ( Site 1401)
    Santiago, Region M. de Santiago 7500710, Chile
  • Pontificia Universidad Catolica de Chile ( Site 1407)
    Santiago, Region M. de Santiago 8330034, Chile
  • Universidad de Chile - Hospital Clínico Universidad de Chile-Inmunologia Alergia y VIH ( Site 1400)
    Santiago, Region M. de Santiago 8380420, Chile
  • Cardio Sur ( Site 1409)
    Santiago, Region M. de Santiago 8910259, Chile
  • Hospital Universitario San Ignacio-Infectious ( Site 1501)
    Bogotá, Bogota D.C. 110231, Colombia
  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 1502)
    Bogotá, Bogota D.C. 111321, Colombia
  • Fundación Valle del Lili ( Site 1500)
    Cali, Valle del Cauca Department 760032, Colombia
  • Rambam Health Care Campus-Institute of Allergy, Clinical Immunology, ( Site 1901)
    Haifa, 3109601, Israel
  • Hadassah Medical Center-Infecious Disease ( Site 1902)
    Jerusalem, 9112001, Israel
  • Sheba Medical Center-HIV unit ( Site 1903)
    Ramat Gan, 5262100, Israel
  • Sourasky Medical Center ( Site 1904)
    Tel Aviv, 64239, Israel
  • National Hospital Organization Nagoya Medical Center ( Site 2103)
    Nagoya, Aichi-ken 460-0001, Japan
  • Tokyo Metropolitan Komagome Hospital ( Site 2105)
    Bunkyo, Tokyo 113-8677, Japan
  • Tokyo Medical University Hospital ( Site 2104)
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Center Hospital of the National Center for Global Health and Medicine ( Site 2101)
    Shinjyuku-ku, Tokyo 162-8655, Japan
  • National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 21
    Osaka, 540-0006, Japan
  • Christchurch Hospital-Infectious Diseases ( Site 2200)
    Christchurch, Canterbury 8011, New Zealand
  • Clinical Research Puerto Rico ( Site 2400)
    San Juan, 00909, Puerto Rico
  • HOPE Clinical Research ( Site 2401)
    San Juan, 00909, Puerto Rico
  • Kemerovo Regional Center for the Prevention and Control of AIDS and Infectious Diseases ( Site 2505)
    Kemerovo, Kemerovo Oblast 650056, Russia
  • Krasnoyarsk Regional Center for the Prevention and Control of AIDS ( Site 2504)
    Krasnoyarsk, Krasnoyarsk Krai 660049, Russia
  • Republican Clinical Infectious Hospital ( Site 2500)
    Saint Petersburg, Leningradskaya Oblast' 196645, Russia
  • Moscow Infectious Diseases Clinical Hospital Number 2 ( Site 2506)
    Moscow, Moscow 105275, Russia
  • Scientific Advisory Clinical Diagnostic Center Central Resea-Federal AIDS Center ( Site 2502)
    Moscow, Moscow 115035, Russia
  • Saint-Petersburg Center for Prophylactic of AIDS and Infecti-Saint-Petersburg Center for Prophylact
    Saint Petersburg, Sankt-Peterburg 190020, Russia
  • Republican Clinical Hospital for Infectious Diseases A.F. Agafonova ( Site 2503)
    Kazan', Tatarstan, Respublika 420140, Russia
  • Josha Research ( Site 2603)
    Bloemfontein, Free State 9301, South Africa
  • Perinatal HIV Research Unit (PHRU)-Adult Treatment and Research ( Site 2605)
    Johannesburg, Gauteng 2013, South Africa
  • Helen Joseph Hospital-Clinical HIV Research Unit ( Site 2609)
    Johannesburg, Gauteng 2092, South Africa
  • Ezintsha-Clinical Research Site ( Site 2607)
    Johannesburg, Gauteng 2193, South Africa
  • Private Practice Dr. Marleen de Jager ( Site 2600)
    Pretoria, Gauteng 0083, South Africa
  • Wentworth Hospital ( Site 2604)
    Durban, KwaZulu-Natal 4052, South Africa
  • Family Clinical Research Unit (Fam-Cru)-Adult Infectious Diseases ( Site 2608)
    Cape Town, Western Cape 7505, South Africa
  • Desmond Tutu Health Foundation ( Site 2602)
    Cape Town, Western Cape 7925, South Africa
  • Be Part Yoluntu Centre ( Site 2601)
    Paarl, Western Cape 7646, South Africa
  • University Hospital Basel-Infectiology ( Site 2802)
    Basel, Canton of Basel-City 4056, Switzerland
  • Hôpitaux Universitaires de Genève (HUG)-Infectious Disease Department ( Site 2804)
    Geneva, Canton of Geneva 1211, Switzerland
  • Cantonal Hospital St.Gallen ( Site 2801)
    Sankt Gallen, Canton of St. Gallen 9007, Switzerland
  • UniversitätsSpital Zürich ( Site 2800)
    Zurich, Canton of Zurich 8091, Switzerland
  • Ospedale Regionale di Lugano, Sede Civico-Servizio Malattie Infettive ( Site 2805)
    Lugano, Canton Ticino 6903, Switzerland
  • Inselspital Bern-Inselspital Infektiologie ( Site 2803)
    Bern, 3010, Switzerland
  • Kaohsiung Veterans General Hospital ( Site 2901)
    Kaohsiung City, 81362, Taiwan
  • University Hospitals Sussex NHS Foundation Trust ( Site 3004)
    East Sussex, Brighton And Hove BN2 1ES, United Kingdom
  • Southmead Hospital ( Site 3003)
    Bristol, Bristol, City of BS10 5NB, United Kingdom
  • Royal Free Hospital ( Site 3002)
    London, England NW32QG, United Kingdom
  • King's College Hospital ( Site 3001)
    London, London, City of SE5 9RL, United Kingdom
  • North Manchester General Hospital ( Site 3005)
    Crumpsall, Manchester M8 5RB, United Kingdom
08

References and documents

Publications

  • Diamond TL, Grandhi A, Fuszard M, Xu Y, Nwoke U, Zhang Y, Klopfer SO, Eves K, Benner J, Li M, Greaves W, Lahoulou R, Kim J, Fox MC, Asante-Appiah E. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA. J Infect Dis. 2026 May 29:jiag257. doi: 10.1093/infdis/jiag257. Online ahead of print. PubMed 42213454 ↗

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Oct 2025, 30 months.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 30 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
Mar 13, 2023
StartActual
Mar 17, 2023
Primary completionActual
Oct 16, 2025
CompletionEst.
Sep 6, 2028
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05766501
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
Mar 17, 2023
Primary completion
Oct 16, 2025
Completion
Sep 6, 2028 (estimated)
Last update
Dec 17, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion